Circulating extracellular vesicle-enriched fraction in heart failure with reduced ejection fraction and incident cancer

Clicks: 6
ID: 337500
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #79 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Aims Previous studies found increased cancer incidence in patients with heart failure with reduced ejection fraction (HFrEF). We sought to explore the biological correlates of the association of HFrEF with cancer in humans. Methods and results: Among participants in the GISSI-HF trial with HFrEF and available baseline plasma samples, we selected those who developed solid cancer (cases) and matched them with controls without cancer by age, sex, NYHA class, and follow-up duration. We isolated the plasma extracellular vesicle (EV)-enriched fraction, in which EVs were confirmed by western blot for CD9, FLOTILLIN-1, ALIX and TSG101, and by nanoparticle tracking analysis (mean particle diameter <200 nm). The protein content of EV preparations was characterized by nanoliquid chromatography-high resolution tandem mass spectrometry. Of 940 identified proteins, 148 were differentially expressed between EV preparations from cases (EVs-cases) and controls (EVs-controls) and were related to biological functions implicated in cancer growth, particularly apoptosis and spliceosome/transcriptome regulation. Next, we explored the effects of EVs-cases and EVs-controls in MCF7 breast cancer cells and run confirmatory experiments with another 2 cell lines, HCT116 (colon) and A549 (lung). Apoptosis, as determined by caspase 3 cleavage, was blunted by EVs-cases in MCF7, but not in HCT116 and A549 cells. Screening qPCR pointed out NR3C1, encoding glucocorticoid receptor, as a spliceosome/transcription modulator affected by EVs-cases. Targeted qPCR confirmed that it was reduced by EVs-cases in A549 cells. Conclusions Circulating EV-enriched fractions from patients with HFrEF and incident cancer have a distinct proteomic signature and might modulate human cancer cell biology.
Reference Key
openalex_W7223922518 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors E Bianconi, Antonella De Palma, Davide Perico, Silvia Bruno, Francesca Fumagalli, Enrico Nicolis, E Rulli, Davide Ceresa, Ambra Costa, Chiara Vitale, Roberto Latini, Pierluigi Mauri, Pietro Ameri
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag180
URL
https://doi.org/10.1093/ehjopen/oeag180
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.